<DOC>
	<DOC>NCT00779428</DOC>
	<brief_summary>The primary purpose of this study is to provide treatment to patients who have participated on a prior protocol investigating Tanespimycin (KOS-953,17-AAG)</brief_summary>
	<brief_title>Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Age &gt;= 18 years Participated in and completed a previous Tanespimycin protocol without evidence of unacceptable toxicity and is deemed by the Investigator to be deriving benefit from the Tanespimycin drug as defined in the previous protocol All patients must rollover to this continuation protocol within 30 days of the last dose of Tanespimycin in the previous protocol, unless previously approved by the Medical Monitor All Adverse Events from the prior protocol, must have resolved to NCI CTCAE (v. 3.0) Grade &lt;= 2 The following laboratory results, within 10 days of Tanespimycin administration: Hemoglobin &gt;= 8 g/dL Absolute neutrophils count &gt;= 1.0x 10*9* /L Platelet count &gt;= 50 x 10*9* /L Serum bilirubin &lt;= 2 x ULN AST &lt;= 2.5 ULN Serum creatinine &lt;= 2 x ULN ECOG performance status of 0, 1 or 2 Signed informed consent Preexisting neuropathy of CTCAE Grade &gt;= 3 due to any cause Documented hypersensitivity reaction of CTCAE Grade &gt;= 3 to prior therapy containing Cremophor (for those patients receiving Tanespimycin Injection) Pregnant or breastfeeding women Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic), excluding Tanespimycin within 21 days prior to receipt of study medication Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>This is an open-label continuing treatment protocol in patients with advanced malignancies who will receive Tanespimycin</keyword>
</DOC>